Enriching Global Perspectives Through a Regional Lens: Recognition, Assessment, and Management of Tardive Dyskinesia in Southeast Asia

Roongroj Bhidayasiri, Jin Kiat Ang, Kok Yoon Chee, Roger Ho, Ahmad Shahir Mawardi, Adhi Wibowo Nurhidayat, Pongsatorn Paholpak, Pornjira Pariwatcharakul, Thitima Sanguanvichaikul, E K Ung, Natalia Dewi Wardani, B.t. Thomas YeoJournal of Movement Disorders 2025 · DOI

Introduction

Tardive Dyskinesia (TD) is a persistent and often irreversible movement disorder resulting from long-term exposure to dopamine receptor-blocking agents (DRBAs), such as antipsychotics and certain antiemetics. While global prevalence is estimated at approximately 25%, the condition remains significantly under-addressed in Southeast Asia (SEA). This paper presents the first regional consensus aimed at bridging the "diagnostic gap" and standardizing care for patients in this region.

The Diagnostic Gap and Barriers to Care

A critical finding of the expert panel is a staggering 90% underrecognition rate of TD in Southeast Asia. Although clinical records frequently note abnormal movements, formal diagnoses are rare. This discrepancy is driven by several systemic and clinical factors, including high patient volumes and a lack of familiarity with standardized assessment tools.

Challenges and barriers to the recognition, assessment, and diagnosis of Tardive Dyskinesia.

As illustrated in the figure above, barriers range from time constraints in busy clinical settings to a lack of specialized training in neurological assessments. Furthermore, clinicians often prioritize primary psychiatric symptoms, such as psychosis or suicidal ideation, over treatment-emergent side effects like dyskinesia. The panel also noted that medicolegal concerns regarding treatment-emergent adverse effects can lead to under-reporting if symptoms are not promptly addressed.

Methodology: The RAND-UCLA Consensus

To address these challenges, a panel of 13 specialists (neurologists and psychiatrists) from Indonesia, Malaysia, Singapore, and Thailand utilized the modified RAND-UCLA Appropriateness Method. This formal process involved iterative rounds of voting on 40 clinical scenarios using a 9-point Likert scale. The consensus was grounded in a structured review of regional prevalence data—which ranges from 20.3% in the Philippines to 35.9% in Malaysia.

Key Clinical Recommendations

The consensus provides a clear framework for improving patient outcomes through standardized screening and precise nomenclature:

  • Standardized Screening: All patients on antipsychotics should undergo screening every six months. To accommodate time-constrained environments, the panel suggests a pragmatic "mini-AIMS" orofacial exam taking approximately 30 seconds as a screening tool.
  • Refining Nomenclature: The authors advocate for retiring the vague umbrella term "Extrapyramidal Symptoms" (EPS). Precise diagnosis is essential because disorders like akathisia, dystonia, and TD require distinct therapeutic approaches.
  • Diagnostic Gold Standard: The Schooler–Kane AIMS (Abnormal Involuntary Movements Scale) criteria are recommended as the primary tool for formal diagnosis.

Management and Treatment

The panel reached a strong consensus on the hierarchy of management. The recommended first step involves switching from first-generation to second-generation antipsychotics where clinically appropriate. For moderate-to-severe cases, Vesicular Monoamine Transporter 2 (VMAT-2) inhibitors, such as valbenazine, are now recommended as first-line therapy. While Vitamin B6 (pyridoxine) may serve as an adjunct for milder cases, VMAT-2 inhibitors offer the most robust evidence-based intervention.

Conclusion and Future Directions

While this consensus marks a significant step forward, limitations remain regarding geographic representation across all eleven SEA nations. Future efforts must focus on expanding these guidelines and advocating for policy changes to improve the availability and reimbursement of VMAT-2 inhibitors, ensuring that these regional standards can be effectively implemented in diverse clinical settings across Southeast Asia.

Summary updated

BibTeX
@article{bhidayasiri2025enriching,
  author = {Roongroj Bhidayasiri and Jin Kiat Ang and Kok Yoon Chee and Roger Ho and Ahmad Shahir Mawardi and Adhi Wibowo Nurhidayat and Pongsatorn Paholpak and Pornjira Pariwatcharakul and Thitima Sanguanvichaikul and E K Ung and Natalia Dewi Wardani and B.T. Thomas Yeo},
  title = {{Enriching Global Perspectives Through a Regional Lens: Recognition, Assessment, and Management of Tardive Dyskinesia in Southeast Asia}},
  journal = {Journal of Movement Disorders},
  year = {2025},
  doi = {10.14802/jmd.25146},
}
Figure